LLY - Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron Analyst Says | Benzinga
On Monday, Structure Therapeutics Inc. (NASDAQ:GPCR) revealed 12-week topline obesity data from its Phase 2a study of GSBR-1290.
In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks.
Cantor Fitzgerald maintains its bullish views on Structure Therapeutics and keeps the Overweight rating with a price target of $65.
The analyst says, “now have more conviction that ‘1290 is very competitive with Eli Lilly And Co’s (NYSE:LLY) orforglipron on efficacy and data from ...